U.S. flag

An official website of the United States government

NM_022089.4(ATP13A2):c.3084-10G>T AND multiple conditions

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Jul 12, 2017
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000528900.1

Allele description [Variation Report for NM_022089.4(ATP13A2):c.3084-10G>T]

NM_022089.4(ATP13A2):c.3084-10G>T

Gene:
ATP13A2:ATPase cation transporting 13A2 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
1p36.13
Genomic location:
Preferred name:
NM_022089.4(ATP13A2):c.3084-10G>T
HGVS:
  • NC_000001.11:g.16986966C>A
  • NG_009054.1:g.29963G>T
  • NM_001141973.3:c.3069-10G>T
  • NM_001141974.3:c.2952-10G>T
  • NM_022089.4:c.3084-10G>TMANE SELECT
  • LRG_834t1:c.3084-10G>T
  • LRG_834:g.29963G>T
  • NC_000001.10:g.17313461C>A
  • NM_022089.3:c.3084-10G>T
Links:
dbSNP: rs368908107
NCBI 1000 Genomes Browser:
rs368908107
Molecular consequence:
  • NM_001141973.3:c.3069-10G>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001141974.3:c.2952-10G>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_022089.4:c.3084-10G>T - intron variant - [Sequence Ontology: SO:0001627]

Condition(s)

Name:
Kufor-Rakeb syndrome (KRS)
Synonyms:
Park 9; Pallidopyramidal degeneration with supranuclear upgaze paresis, and dementia; PARKINSON DISEASE 9, AUTOSOMAL RECESSIVE, JUVENILE-ONSET
Identifiers:
MONDO: MONDO:0011706; MedGen: C1847640; Orphanet: 306674; Orphanet: 314632; OMIM: 606693
Name:
Autosomal recessive spastic paraplegia type 78
Identifiers:
MONDO: MONDO:0014975; MedGen: C5567893; OMIM: 617225

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000640195Invitae
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Uncertain significance
(Jul 12, 2017)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240-242.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Invitae, SCV000640195.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

This sequence change falls in intron 26 of the ATP13A2 gene. It does not directly change the encoded amino acid sequence of the ATP13A2 protein. This variant is present in population databases (rs368908107, ExAC 0.002%). This variant has not been reported in the literature in individuals with ATP13A2-related disease. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Jul 16, 2023